Naz Rahman
Stock Analyst at Maxim Group
(0.30)
# 4,346
Out of 5,090 analysts
35
Total ratings
20%
Success rate
-44.69%
Average return
Main Sectors:
Stocks Rated by Naz Rahman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KZIA Kazia Therapeutics | Maintains: Buy | $15 → $20 | $15.05 | +32.89% | 1 | Oct 2, 2025 | |
| AYTU Aytu BioPharma | Maintains: Buy | $9 → $7 | $2.22 | +215.32% | 2 | Sep 25, 2025 | |
| GLMD Galmed Pharmaceuticals | Downgrades: Hold | n/a | $1.12 | - | 1 | Apr 4, 2025 | |
| NVCT Nuvectis Pharma | Initiates: Buy | $17 | $6.71 | +153.35% | 1 | Apr 2, 2025 | |
| SLXN Silexion Therapeutics | Maintains: Buy | $135 → $75 | $3.02 | +2,383.44% | 2 | Mar 20, 2025 | |
| VKTX Viking Therapeutics | Maintains: Buy | $120 → $70 | $38.55 | +81.58% | 5 | Feb 7, 2025 | |
| NRSN NeuroSense Therapeutics | Downgrades: Hold | n/a | $1.17 | - | 2 | Dec 16, 2024 | |
| CING Cingulate | Upgrades: Buy | n/a | $3.99 | - | 4 | Nov 20, 2024 | |
| PALI Palisade Bio | Maintains: Buy | $23 → $8 | $1.80 | +344.44% | 7 | Nov 13, 2024 | |
| PRFX PainReform | Downgrades: Hold | n/a | $0.96 | - | 2 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $3 | $0.77 | +290.88% | 1 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $525 → $140 | $12.09 | +1,057.98% | 2 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $455.48 | - | 1 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $0.28 | - | 3 | Nov 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $1.58 | +279.75% | 1 | Feb 25, 2022 |
Kazia Therapeutics
Oct 2, 2025
Maintains: Buy
Price Target: $15 → $20
Current: $15.05
Upside: +32.89%
Aytu BioPharma
Sep 25, 2025
Maintains: Buy
Price Target: $9 → $7
Current: $2.22
Upside: +215.32%
Galmed Pharmaceuticals
Apr 4, 2025
Downgrades: Hold
Price Target: n/a
Current: $1.12
Upside: -
Nuvectis Pharma
Apr 2, 2025
Initiates: Buy
Price Target: $17
Current: $6.71
Upside: +153.35%
Silexion Therapeutics
Mar 20, 2025
Maintains: Buy
Price Target: $135 → $75
Current: $3.02
Upside: +2,383.44%
Viking Therapeutics
Feb 7, 2025
Maintains: Buy
Price Target: $120 → $70
Current: $38.55
Upside: +81.58%
NeuroSense Therapeutics
Dec 16, 2024
Downgrades: Hold
Price Target: n/a
Current: $1.17
Upside: -
Cingulate
Nov 20, 2024
Upgrades: Buy
Price Target: n/a
Current: $3.99
Upside: -
Palisade Bio
Nov 13, 2024
Maintains: Buy
Price Target: $23 → $8
Current: $1.80
Upside: +344.44%
PainReform
Oct 24, 2024
Downgrades: Hold
Price Target: n/a
Current: $0.96
Upside: -
Jul 26, 2024
Initiates: Buy
Price Target: $3
Current: $0.77
Upside: +290.88%
Mar 15, 2024
Maintains: Buy
Price Target: $525 → $140
Current: $12.09
Upside: +1,057.98%
Jan 31, 2024
Downgrades: Hold
Price Target: n/a
Current: $455.48
Upside: -
Nov 17, 2023
Downgrades: Hold
Price Target: n/a
Current: $0.28
Upside: -
Feb 25, 2022
Initiates: Buy
Price Target: $6
Current: $1.58
Upside: +279.75%